Physician profile
Michael M Pollock
NPI 1457303224
$44,767.55
in general payments reported to CMS, 2019-2025
24 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $8,750 · 2021: $4,565 · 2022: $502 · 2023: $181 · 2024: $653 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,114.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $42,366.04 | 2019-2024 | |
| Ethicon US, LLC | $894.16 | 2019-2025 | Ethicon, Vistaseal, Harmonic |
| Abbvie INC. | $308.59 | 2023-2025 | |
| Tas Medical, INC. | $282.04 | 2024 | |
| Davol INC. | $247.01 | 2019-2023 | Phasix Mesh |
| Allergan, INC. | $107.76 | 2021-2022 | |
| Tela Bio, INC. | $94.92 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Becton, Dickinson and Company | $65.65 | 2022 | |
| Acera Surgical, INC. | $51.72 | 2022-2023 | Restrata Wound Matrix |
| Kerecis Limited | $48.43 | 2022-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Medtronic, INC. | $41.33 | 2022 | |
| Smith+Nephew, INC. | $35.84 | 2020-2022 | |
| Integra Lifesciences Corporation | $33.41 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Acell, INC. | $23.61 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $21.58 | 2024 | Gore Synecor Biomaterial |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $20.80 | 2025 | Myrisk |
| La Jolla Pharmaceutical Company | $17.80 | 2024 | Xerava |
| Alexion Pharmaceuticals, INC. | $17.55 | 2022 | |
| Haemonetics Corporation | $16.79 | 2020 | |
| Osiris Therapeutics INC. | $16.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2024 | Andexxa |
| Misonix INC | $14.57 | 2020 | |
| Innocoll Pharmaceuticals Limited | $13.54 | 2021 | |
| Teleflex LLC | $12.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.